Strongbridge Biopharma (SBBP) – Trader Talk
-
Companies with NDRs 5/12
-
Strongbridge Biopharma (SBBP) climbs 42% after announcing results from Phase 3 study evaluating RECORLEV for treatment of endogenous Cushing’s syndrome
-
Back to SBBP Stock Lookup